Monitor the closing of the Xodus Medical acquisition and the associated increase in STERIS's leverage. The new $1.6B revamp of the revolving credit facility suggests ongoing liquidity management.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $264.32entry
- T+1 · 15h ago −0.91%α +1.00% · $261.91
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
STERIS priced a $1.5 billion senior notes offering ($750M 5.650% notes due 2033 and $750M 5.875% notes due 2036) to fund the pending acquisition of Xodus Medical, Inc. The offering is expected to close on November 24, 2026, and the notes will be guaranteed by STERIS plc and its subsidiaries. The filing is a routine debt capital markets transaction to finance a previously announced acquisition.
Key Facts
- STERIS Irish FinCo Unlimited Company priced $1.5 billion aggregate principal amount of senior notes on November 9, 2026
- The offering consists of $750 million of 5.650% Senior Notes due 2033 and $750 million of 5.875% Senior Notes due 2036
- Notes are guaranteed on a senior unsecured basis by STERIS plc, STERIS Corporation, and STERIS Limited
- Net proceeds will fund the pending acquisition of Xodus Medical, Inc., along with borrowings under a $500 million delayed draw term loan and cash on hand
- The Issuer also intends to enter into a $1.6 billion senior unsecured revolving credit facility
- Closing expected on or about November 24, 2026, subject to customary conditions
Financial Impact
$1.5 billion aggregate principal amount of new senior notes issued; proceeds used to fund acquisition of Xodus Medical, Inc.
Risk Factors
- Increased leverage from $1.5B in new debt and $500M term loan may pressure credit ratings
- Acquisition integration risk for Xodus Medical may affect financial performance
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-458364 |
| Document: d195273d8k.htm | 0001193125-26-458364 |
| Document: 0001193125-26-458364-index-headers.html | 0001193125-26-458364 |
| Document: 0001193125-26-458364-index.html | 0001193125-26-458364 |
| Document: 0001193125-26-458364.txt | 0001193125-26-458364 |
Track record
21 reports on STE
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.96% at T+20 after the Oct 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 20
- Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $264.32 Now $261.91 −0.91% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $261.91 +3.34% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $261.91 +2.20% settles Nov 18
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
- Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $261.91 +12.82% ▲ +9.47% +14.19% vs SPY
- Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $261.91 +18.25% ▲ +3.17% +3.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers